Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating intensity-modulated post-operative radiation therapy I-PORT combined with standard chemotherapy or immunotherapy versus standard therapy alone for patients with non-small cell lung cancer NSCLC who have remaining lymph node cancer after surgery. This phase II trial aims to determine if I-PORT improves disease-free survival and assesses its impact on severe late cardiopulmonary side effects compared to standard care. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy or immunotherapy alone, while the other undergoes I-PORT daily Monday through Friday over 5 to 6 weeks, starting 4 to 12 weeks after surgery, followed by standard therapy. Throughout the study, patients have CT andor MRI scans, FDG-PET scans, and blood samples collected. Treatment continues until disease progression or unacceptable side effects occur. After completing treatment, participants are followed every 3 months for 2 years and then every 6 months for an additional 3 years. The study measures disease-free survival up to 5 years, overall survival at 2 and 5 years, rates of local and distant cancer control, and patient-reported symptoms related to heart and lung health. Safety is closely monitored, focusing on acute and late side effects affecting the heart and lungs.
Actively Recruiting
Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.
Actively Recruiting
Researchers are studying adults newly diagnosed with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancers who are starting systemic cancer treatments such as chemotherapy or immune checkpoint inhibitors. The purpose is to understand how cannabis and cannabinoid use relates to cancer-related symptoms over one year. This observational study enrolls 2000 participants to explore these associations in community oncology settings. Participants do not receive any experimental treatments but complete surveys and have their medical records reviewed. Assessments occur monthly for up to 12 months, capturing cannabis use, perceived benefits and harms, and adverse effects alongside symptom tracking. There is an optional sub-study for some participants receiving immune checkpoint inhibitors at specific cancer centers. During the study, participants complete monthly surveys either online at home, in clinic, or other locations, and their medical records are reviewed for treatment and symptom information. Researchers measure cancer-related symptoms and cannabis use patterns over time. The study monitors participants for up to one year to evaluate symptom changes and cannabis-related effects, with no intervention administered by the study team.
Actively Recruiting
Healthy Volunteer
Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of combining ASTX727 and venetoclax with or without enasidenib in treating older adults newly diagnosed with acute myeloid leukemia AML who have a mutation in the IDH2 gene. This phase II trial aims to see if adding enasidenib to the usual treatment can improve outcomes by reducing measurable residual disease-negative complete remission rates in patients who are either older or unfit for standard therapy. Participants are randomly assigned to one of two treatment groups. One group receives oral ASTX727 daily on days 1-5 and venetoclax daily on days 1-28 of each 28-day cycle. The other group receives the same treatment plus oral enasidenib daily on days 1-28. Treatment cycles continue every 28 days unless disease progression or unacceptable side effects occur. Throughout the trial, blood samples, bone marrow aspirations, and biopsies are collected to monitor disease and treatment effects. During the study, participants undergo regular evaluations including blood tests and bone marrow procedures to assess remission status and measurable residual disease. After completing treatment, participants are followed monthly for the first year, then every two months in the second year, every three months in the third year, and every six months up to five years or until death. Researchers measure remission rates, survival outcomes, and adverse events to understand the treatments impact on AML with IDH2 mutation.
Actively Recruiting
Healthy Volunteer
This trial is studying advanced practice providers APPs who work in cancer care but may not regularly participate in clinical research at community oncology sites. It evaluates whether a mentorship and education program called COACH-APP can improve APPs confidence in their ability to engage in clinical research, known as research self-efficacy. The study aims to see if this program helps APPs integrate more meaningfully into research teams and potentially improves patient care and access to clinical trials. Participants are divided into groups where one receives the COACH-APP intervention, which includes completing a 6-module clinical research workshop over 2 hours, receiving a clinical trials research manual, and participating in five mentoring sessions lasting 15-60 minutes over 12 months. The comparison group receives only access to the workshop and manual for 12 months. Additionally, mentors providing the COACH-APP mentorship and selected research care team members participate in qualitative interviews to assess the interventions impact. During the study, participants complete surveys and interviews to measure changes in research self-efficacy, engagement with the National Cancer Institutes community oncology research program, integration into research care teams, and practice-level study activity over 12 to 24 months. The trial also evaluates the feasibility, acceptability, and appropriateness of the COACH-APP program. Participation involves training sessions, mentoring, surveys, and interviews over a 12-month period with follow-up assessments extending up to 24 months.
Actively Recruiting
Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating an online educational program called Current Together After Cancer CTAC to see if it helps colorectal cancer survivors who had surgery receive follow-up care that matches current guidelines. This phase III trial focuses on patients with stage II or III colorectal cancer who have had their tumors surgically removed. The study aims to improve patients knowledge about surveillance, their confidence in managing follow-up care, and satisfaction with the involvement of a supporter in their care. Patients in the trial are randomly assigned to one of two groups. One group and their supporter get access to the CTAC intervention website, which contains educational content and interactive modules related to colorectal cancer surveillance. The other group and their supporter receive access to a general health education website. Participants may review their assigned website as often as they like for up to 16 months. During the study, participants will complete questionnaires at baseline, 3 months, and 16 months to assess knowledge, self-efficacy, cancer worry, preferences, and satisfaction with supporter engagement. Researchers will measure whether patients receive colorectal cancer surveillance aligned with guidelines at 16 months. The study also explores how supporters participation relates to patient outcomes. Participants may be contacted via email or phone for study activities and are encouraged to complete all scheduled assessments.
Actively Recruiting
Researchers are evaluating whether high-dose gabapentin can reduce the need for opioid pain medications in patients undergoing chemotherapy and radiation for squamous cell carcinoma of the head and neck. Oral mucositis, a painful side effect of radiation, often requires opioid treatment which can cause many side effects and long-term use concerns. This phase III trial aims to see if gabapentin can better manage mucositis pain compared to placebo. Participants are randomly assigned to receive either gabapentin or a placebo starting at the eighth radiation treatment. Both groups receive standard chemotherapy, radiation, and pain care. Gabapentin or placebo is given orally once daily on day 1, twice daily on day 2, and three times daily from day 3 onward. Treatment continues until mucositis symptoms improve and other pain medications stop, followed by a gradual dose reduction over 11 days. Blood samples are collected throughout. During the study, participants opioid use, pain levels, and quality of life are regularly assessed. Follow-up visits occur at 4 weeks, 3 months, and 6 months after chemoradiation ends. Researchers monitor pain scores, opioid use duration, adverse effects, feeding tube needs, and other health measures to understand gabapentins impact on pain and treatment outcomes.
Actively Recruiting
Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.
1-10 of 18
1